$NBIX Neurocrine Biosciences  Q3 Non-GAAP EPS of $0.97 misses by $0.28; GAAP EPS of -$0.62 misses by $0.68. Revenue of $258.5M (+16.4% Y/Y) misses by $24.09M. Total cash and cash equivalents and debt securities available-for-sale of $1,126.1M. FY20 guidance: Combined GAAP R&D and SG&A expenses of $880M-900M; combined non-GAAP R&D and SG&A expenses of $590M-610M